CD151

Across TCGA pan-cancer cohorts, CD151 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD151 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD151 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD151 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where CD151 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.588	0.962	<.001	39	view →
GBM	DFS	Tertile	All	0.276	0.514	<.001	23	view →
HNSC	DFS	Median	IV	0.817	0.538	.001	21	view →
LUAD	OS	Quartile	II,III,IV	0.350	0.772	.008	8	view →
LSCC	OS	Tertile	All	0.909	1.000	.010	7	view →
PDAC	DFS	Quartile	III,IV	0.497	0.971	.026	7	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD151–CCRCC (DFS)

Open the CCRCC breakdown →